1126602-50-3

Upstream product

• 613-73-0 1,2-phenylenediacetonitrile 
• 17532-66-0 ethyl 2-[2-(2-ethoxy-2-oxoethyl)phenyl]acetate 
• 1126602-49-0 2-amino-3H,4H,9H-indeno[2,1-d]pyrimidin-4-one 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 1126602-51-4 N₄-(2-isopropylphenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-53-6 N₄-(3-fluorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-62-7 N₄-(3-chloro-4-fluorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-58-1 N₄-(4-(trifluoromethyl)phenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-52-5 N₄-(4-isopropylphenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-63-8 N₄-(4-chloro-2-fluorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-59-2 N₄-(3-methoxyphenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-56-9 N₄-(4-chlorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-60-5 N₄-phenyl-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-54-7 N₄-(3-chlorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-61-6 N₄-(3-bromophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-55-8 N₄-(4-fluorophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 
• 1126602-57-0 N₄-(4-bromophenyl)-9H-indeno[2,1-d]pyrimidine-2,4-diamine 

Relevant academic research and scientific papers

Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents

We designed, synthesized and evaluated 13 novel tricyclic indeno[2,1-d]pyrimidines as RTK inhibitors. These analogues were synthesized via a Dieckmann condensation of 1,2-phenylenediacetonitrile followed by cyclocondensation with guanidine carbonate to af

TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF

The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.